ロード中...
Bortezomib attenuates HIF-1- but not HIF-2-mediated transcriptional activation
Bortezomib is the first proteasomal inhibitor (PI) to be used therapeutically for treating relapse cases of multiple myeloma and mantle cell lymphoma. A proposed mechanism for its action is that it prevents the proteasomal degradation of proapoptotic proteins, leading to enhanced apoptosis. Although...
保存先:
| 出版年: | Oncol Lett |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
D.A. Spandidos
2015
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4579903/ https://ncbi.nlm.nih.gov/pubmed/26622817 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2015.3545 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|